A Randomized, Double-Blind, Placebo And Active-Controlled, Parallel Group Study To Evaluate The Dose-Related Efficacy And Safety Of PS433540 In Subjects With Hypertension.

Trial Profile

A Randomized, Double-Blind, Placebo And Active-Controlled, Parallel Group Study To Evaluate The Dose-Related Efficacy And Safety Of PS433540 In Subjects With Hypertension.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2011

At a glance

  • Drugs Sparsentan (Primary) ; Irbesartan
  • Indications Hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Sep 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 06 Mar 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 02 Feb 2009 Positive interim results data were reported in a Ligand media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top